OBJECTIVES:People with co-occurring severe mental illness and a substance use disorder are at markedly elevated risk of infection from HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV), but they generally do not receive basic recommended screening or preventive and treatment services. Barriers to services include lack of programs offered by mental health providers and client refusal of available services. Clients from racial-ethnic minority groups are even less likely to accept recommended services. The intervention tested was designed to facilitate integrated infectious disease programming in mental health settings and to increase acceptance of such services among clients. METHODS: A randomized controlled trial (N=236) compared enhanced treatment as usual (control) with a brief intervention to deliver best-practice services for blood-borne diseases in an urban sample of clients with co-occurring disorders who were largely from racial-ethnic minority groups. The "STIRR" intervention included Screening for HIV and HCV risk factors, Testing for HIV and hepatitis, Immunization against hepatitis A and B, Risk reduction counseling, and medical treatment Referral and support at the site of mental health care. RESULTS: Clients randomly assigned to the STIRR intervention had high levels (over 80%) of participation and acceptance of core services. They were more likely to be tested for HBV and HCV, to be immunized against hepatitis A virus and HBV, and to increase their knowledge about hepatitis and reduce their substance abuse. However, they showed no reduction in risk behavior, were no more likely to be referred to care, and showed no increase in HIV knowledge. Intervention costs were $541 per client (including $234 for blood tests). CONCLUSIONS: STIRR appears to be efficacious in providing a basic, best-practice package of interventions for clients with co-occurring disorders.
RCT Entities:
OBJECTIVES:People with co-occurring severe mental illness and a substance use disorder are at markedly elevated risk of infection from HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV), but they generally do not receive basic recommended screening or preventive and treatment services. Barriers to services include lack of programs offered by mental health providers and client refusal of available services. Clients from racial-ethnic minority groups are even less likely to accept recommended services. The intervention tested was designed to facilitate integrated infectious disease programming in mental health settings and to increase acceptance of such services among clients. METHODS: A randomized controlled trial (N=236) compared enhanced treatment as usual (control) with a brief intervention to deliver best-practice services for blood-borne diseases in an urban sample of clients with co-occurring disorders who were largely from racial-ethnic minority groups. The "STIRR" intervention included Screening for HIV and HCV risk factors, Testing for HIV and hepatitis, Immunization against hepatitis A and B, Risk reduction counseling, and medical treatment Referral and support at the site of mental health care. RESULTS: Clients randomly assigned to the STIRR intervention had high levels (over 80%) of participation and acceptance of core services. They were more likely to be tested for HBV and HCV, to be immunized against hepatitis A virus and HBV, and to increase their knowledge about hepatitis and reduce their substance abuse. However, they showed no reduction in risk behavior, were no more likely to be referred to care, and showed no increase in HIV knowledge. Intervention costs were $541 per client (including $234 for blood tests). CONCLUSIONS: STIRR appears to be efficacious in providing a basic, best-practice package of interventions for clients with co-occurring disorders.
Authors: Paula M Frew; Richard A Crosby; Laura F Salazar; Lauren P Gallinot; Lawrence O Bryant; David R Holtgrave Journal: J Natl Med Assoc Date: 2008-07 Impact factor: 1.798
Authors: Marvin S Swartz; Jeffrey W Swanson; Michael J Hannon; Hayden S Bosworth; Fred C Osher; Susan M Essock; Stanley D Rosenberg Journal: Psychiatr Serv Date: 2003-06 Impact factor: 3.084
Authors: Stanley D Rosenberg; Jeffrey W Swanson; George L Wolford; Fred C Osher; Marvin S Swartz; Susan M Essock; Marian I Butterfield; Bryan J Marsh Journal: Psychiatr Serv Date: 2003-06 Impact factor: 3.084
Authors: Seth Himelhoch; Richard Goldberg; Christine Calmes; Deborah Medoff; Eric Slade; Lisa Dixon; Gerard Gallucci; Stanley Rosenberg Journal: J Community Psychol Date: 2011-02-02
Authors: Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht Journal: World Psychiatry Date: 2011-02 Impact factor: 49.548
Authors: Christopher Welsh; Richard Goldberg; Stephanie Tapscott; Deborah Medoff; Stanley Rosenberg; Lisa Dixon Journal: Am J Addict Date: 2012 Mar-Apr
Authors: Eric P Slade; Stanley Rosenberg; Lisa B Dixon; Richard W Goldberg; George L Wolford; Seth Himelhoch; Stephanie Tapscott Journal: Psychiatr Serv Date: 2013-02-01 Impact factor: 3.084